| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_08e518c9469c0d8aed8634dc54203812 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K7-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P11-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K7-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P29-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K7-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-08 |
| filingDate |
2003-04-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2013-05-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_93b782dceecb15c8df4d7d7276879da3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_538b9590a6038a13458eff698fc81b6a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_81b4bc9e4b2a81f04cb7856f833fb38d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_469274540d8bbe2f165582493fd5dc05
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a3188c44bb59c78d4361a5339ace781a |
| publicationDate |
2013-05-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CA-2423876-C |
| titleOfInvention |
Novel selective bradykinin (bk) b1 peptidic receptor antagonists and uses thereof |
| abstract |
The present invention provides for a novel peptidic antagonist for the bradykinin B1 (BKB1) receptor having very good to excellent affinities and selectivity for the BKB, receptor, in vitro and in vivo increase resistance to enzymatic degradation, superior pharmacokinetic properties, capability to significantly reduce microvascular leakage observed alongside diabetic-induced increase in vascular permeability, capability to significantly reduced the state of hyperalgesia alongside diabetes, capability to significantly reduce the infiltration of pro- inflammatory cells and general state of inflammation alongside allergic asthma. |
| priorityDate |
2003-04-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |